… Disclosure: Long MKC, JCI, ITW, SYY, JNJ, PG, PEP, GPC, MCD, ITW, MDT, AFL, MHP, ABT, MO, T, KMB, CLX, XOM, BCR at the time of writing. Disclaimer: The opinions in this document are for informational and educational purposes only and should …
By Stephen Simpson : You would think that a company posting roughly double the industry average revenue growth rate and solid margins should be one of the more highly-valued companies in the sector. Alas, that's not the case with Covidien ( COV ). While I don't want to leave readers with the ...
By Stephen Simpson : Becton Dickinson ( BDX ) has been a single-digit grower for most of the past decade, and that really hasn't seemed to bother anybody. There's nothing wrong with consistent high-quality performance, particularly when accompanied by improving free cash flow conversion. Although
Medical-device maker C . R . Bard ( BCR +1% ) names Aramark executive Christopher Holland as its new CFO. Post your comment!
By Furbonacci : Becton, Dickinson and Company ( BDX ) is a worldwide medical technology company with revenues of $7.87 billion. BDX sports a 2.4% forward annual dividend yield with a payout ratio of only 31% , leaving plenty of room for dividend increases. Some of the larger companies in medical ...
CR Bard ( BCR ) Q1 2012 Earnings Call April 24, 2012 5:00 pm ET Executives Timothy M. Ring - Chairman, Chief Executive Officer and Chairman …
C . R . Bard ( BCR ): Q1 EPS of $1.61 beats by $0.05 . Revenue of $730M (+4.2% Y/Y) misses by $3M . Shares +0.6% AH. ( PR ) Post your comment!
Ladies and gentlemen, thank you for standing by. Welcome to the C . R . Bard , Incorporated First Quarter 2012 Earnings Results Conference Call. At this time, all participants are in a listen-only mode …
By Stephen Simpson : There's little question that Intuitive Surgical ( ISRG ) has been one of the all-time great med-tech stocks and arguably has claim to a spot on the all-time list irrespective of industry. Not only has the company managed to drive strong adoption in selected indications, but ...
By Stephen Simpson : Although this year is looking a little better than last for med-tech stocks, it's still largely a revenue growth-driven phenomenon. To that end, AngioDynamics' ( ANGO ) unimpressive growth has pushed it towards being an afterthought for many investors. While this story is going